Monte Rosa Therapeutics (GLUE) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$0.33.
- Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) fell 1379.31% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 11758.24%. This contributed to the annual value of -$0.98 for FY2024, which is 6258.42% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported EPS (Weighted Average and Diluted) of -$0.33 as of Q3 2025, which was down 1379.31% from -$0.15 recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.57 in Q1 2025 and a low of -$0.71 during Q2 2023
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.33, with a median of -$0.43 in 2024.
- Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) was 20754.72% (2025), while the steepest drop was 1379.31% (2025).
- Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.57 in 2023, then skyrocketed by 131.82% to $0.18 in 2024, then crashed by 281.92% to -$0.33 in 2025.
- Its last three reported values are -$0.33 in Q3 2025, -$0.15 for Q2 2025, and $0.57 during Q1 2025.